Immungeniciteten af en enkelt dosis af en tidligere formulering af ProQuad, var sammenlignelig med immungeniciteten af en enkelt dosis af de individuelle vacciner, der indgik (levende skoldkoppevaccine (Oka/ Merck) og MFR- vaccinen fremstillet af Merck Co., Inc.), som aktuelt anvendes rutinemæssigt til vaccination i nogle lande.
The immunogenicity of a single dose of an earlier formulation of ProQuad was comparable to the immunogenicity of a single dose of its individual component vaccines (Varicella Vaccine live (Oka/ Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.), currently used in routine vaccination in some countries.